ArticleBMC medicine2026

Enhancing oncolytic virotherapy with a tri-specific T-cell engager targeting CD3ε, EpCaM, and 4-1BB: preclinical evaluation and implications for cancer immunotherapy.

Zhongyi Dong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.